Sudo, Kentaro
Hara, Ryusuke
Nakamura, Kazuyoshi
Kita, Emiri
Tsujimoto, Akiko
Yamaguchi, Taketo
Clinical trials referenced in this document:
Documents that mention this clinical trial
Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer
https://doi.org/10.1007/s00280-017-3350-5
Article History
Received: 12 May 2017
Accepted: 1 June 2017
First Online: 8 June 2017
Compliance with ethical standards
:
: Taketo Yamaguchi received research funding from Oncotherapy Science, Inc, Merck Serono Co., Ltd., Taiho Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co., Ltd., NanoCarrier Co., Ltd., and Baxalta Japan Limited, outside the submitted work. Other authors declare no conflict of interest.
: This research did not receive any specific grant from funding agencies.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All study participants provided written informed consent and the study design was approved by the ethical review board of Chiba Cancer Center
: Informed consent was obtained from all individual participants included in the study.